Biofilms are a mounting problem in modern medicine. A leading source of fouling on equipment, patient reinfections, and drug-resistant bacteria, healthcare systems are faced with limited responses. Aequor has developed the Aequor Biofilm Dispersant to address this matter, breeding a DNA sequence from marine microbes into an E. coli-based delivery system to break down these organic barriers and allow other antimicrobials to do their work. ABD is 99% effective against biofilms formed by Gram-negative and Gram-positive bacteria and fungi, is non-destructive, and provokes no bacterial resistance response at effective concentrations, making it sustainably effective. In some cases, there has not been a new antibiotic solution in over 40 years. The feasibility study will examine the viability of the ABD as an antibiotic and drug-additive to improve clinical outcomes and make EU healthcare more sustainable.